N4 Pharma is developing Nuvec®, a potentially ground-breaking nanoparticle drug delivery technology as an alternative to prevailing technologies, with possible applications across cancer therapy and immunology. Initial results of recent formulation work carried out in vivo have demonstrated inconsistencies compared to earlier in vitro studies. In our view, these results are not yet conclusive and the scope of ongoing testing in conjunction with original licensor of the technology provides scope ....
15 Apr 2019
Room for improved outcomes
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Room for improved outcomes
N4 Pharma Plc (N4P:LON) | 0.8 0 0.0% | Mkt Cap: 7.92m
- Published:
15 Apr 2019 -
Author:
Emma Ulker -
Pages:
3
N4 Pharma is developing Nuvec®, a potentially ground-breaking nanoparticle drug delivery technology as an alternative to prevailing technologies, with possible applications across cancer therapy and immunology. Initial results of recent formulation work carried out in vivo have demonstrated inconsistencies compared to earlier in vitro studies. In our view, these results are not yet conclusive and the scope of ongoing testing in conjunction with original licensor of the technology provides scope ....